Cargando…
Effectiveness of Menthacarin on symptoms of irritable bowel syndrome
Irritable bowel syndrome (IBS) and functional dyspepsia (FD) are common functional gastrointestinal disorders with overlapping symptoms. Effectiveness and safety of Menthacarin (Menthacarin® is the active ingredient of the product Carmenthin® [Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, German...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Vienna
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435633/ https://www.ncbi.nlm.nih.gov/pubmed/29728848 http://dx.doi.org/10.1007/s10354-018-0635-1 |
_version_ | 1783406675435192320 |
---|---|
author | Madisch, Ahmed Miehlke, Stephan Labenz, Joachim Stracke, Berenike Köhler, Stephan |
author_facet | Madisch, Ahmed Miehlke, Stephan Labenz, Joachim Stracke, Berenike Köhler, Stephan |
author_sort | Madisch, Ahmed |
collection | PubMed |
description | Irritable bowel syndrome (IBS) and functional dyspepsia (FD) are common functional gastrointestinal disorders with overlapping symptoms. Effectiveness and safety of Menthacarin (Menthacarin® is the active ingredient of the product Carmenthin® [Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany]) in FD treatment were already demonstrated. We assessed the effectiveness of Menthacarin in reducing concomitant IBS-associated symptoms in FD patients. A systematic search to identify eligible double-blind, randomized controlled trials (RCTs) investigating Menthacarin in FD patients and focusing on IBS-associated symptoms was performed. Three out of five identified RCTs included a total of 111 eligible subjects, which allowed for summary statistics and inclusion into subgroup analysis for FD patients with IBS-associated symptoms. With pain intensity values decreasing by 50–75% on average during 28 days of treatment in patients with accompanying IBS, the subgroup analysis indicates beneficial treatment effects of Menthacarin that are similar to those found for FD patients in the primary analyses. The reduction of IBS-associated symptoms in FD patients suggests Menthacarin as a treatment option for IBS patients. |
format | Online Article Text |
id | pubmed-6435633 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Springer Vienna |
record_format | MEDLINE/PubMed |
spelling | pubmed-64356332019-04-15 Effectiveness of Menthacarin on symptoms of irritable bowel syndrome Madisch, Ahmed Miehlke, Stephan Labenz, Joachim Stracke, Berenike Köhler, Stephan Wien Med Wochenschr Original Article Irritable bowel syndrome (IBS) and functional dyspepsia (FD) are common functional gastrointestinal disorders with overlapping symptoms. Effectiveness and safety of Menthacarin (Menthacarin® is the active ingredient of the product Carmenthin® [Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany]) in FD treatment were already demonstrated. We assessed the effectiveness of Menthacarin in reducing concomitant IBS-associated symptoms in FD patients. A systematic search to identify eligible double-blind, randomized controlled trials (RCTs) investigating Menthacarin in FD patients and focusing on IBS-associated symptoms was performed. Three out of five identified RCTs included a total of 111 eligible subjects, which allowed for summary statistics and inclusion into subgroup analysis for FD patients with IBS-associated symptoms. With pain intensity values decreasing by 50–75% on average during 28 days of treatment in patients with accompanying IBS, the subgroup analysis indicates beneficial treatment effects of Menthacarin that are similar to those found for FD patients in the primary analyses. The reduction of IBS-associated symptoms in FD patients suggests Menthacarin as a treatment option for IBS patients. Springer Vienna 2018-05-04 2019 /pmc/articles/PMC6435633/ /pubmed/29728848 http://dx.doi.org/10.1007/s10354-018-0635-1 Text en © The Author(s) 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Article Madisch, Ahmed Miehlke, Stephan Labenz, Joachim Stracke, Berenike Köhler, Stephan Effectiveness of Menthacarin on symptoms of irritable bowel syndrome |
title | Effectiveness of Menthacarin on symptoms of irritable bowel syndrome |
title_full | Effectiveness of Menthacarin on symptoms of irritable bowel syndrome |
title_fullStr | Effectiveness of Menthacarin on symptoms of irritable bowel syndrome |
title_full_unstemmed | Effectiveness of Menthacarin on symptoms of irritable bowel syndrome |
title_short | Effectiveness of Menthacarin on symptoms of irritable bowel syndrome |
title_sort | effectiveness of menthacarin on symptoms of irritable bowel syndrome |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435633/ https://www.ncbi.nlm.nih.gov/pubmed/29728848 http://dx.doi.org/10.1007/s10354-018-0635-1 |
work_keys_str_mv | AT madischahmed effectivenessofmenthacarinonsymptomsofirritablebowelsyndrome AT miehlkestephan effectivenessofmenthacarinonsymptomsofirritablebowelsyndrome AT labenzjoachim effectivenessofmenthacarinonsymptomsofirritablebowelsyndrome AT strackeberenike effectivenessofmenthacarinonsymptomsofirritablebowelsyndrome AT kohlerstephan effectivenessofmenthacarinonsymptomsofirritablebowelsyndrome |